Crohn's Disease Research Studies

Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people.

Investigators

4964-Fischer, Monika

Monika Fischer, MD

Professor of Medicine

60778-Kurada, Satya

Satya Kurada, M.D.

Assistant Professor of Clinical Medicine

Open Research Studies for Crohn's Disease

AbbVie AFFIRM

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 49 weeks, 11 visits

Patient Population: Adult patients with a diagnosis of Crohn's Disease

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

Merck

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 52 Weeks

Patient Population: Adult patients with a diagnosis of Crohn's Disease

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

Takeda VICTRIVA

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 54 Weeks

Patient Population: Adult patients with a diagnosis of Crohn's Disease

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

Roche/Genentech

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 52 Weeks

Patient Population: Adult patients with a diagnosis of Crohn's Disease

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

MTTCD (FMT for Crohn's Disease)

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 6 Months

Patient Population: Adult patients with a diagnosis of Crohn's Disease

Interested in this study? Please contact the IBD research team: i uibd@iu.edu

COMMIT CD

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 56 Weeks

Patient Population: Adult patients with a diagnosis of Crohn's Disease and a BMI greater than or equal to 30 or BMI greater than or equal to 27 with comorbidity (hypertension, T2DM, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

Janssen ICONIC-CD

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 58 Weeks

Patient Population: Adult patients with a diagnosis of Crohn's Disease

Interested in this study? Please contact the IBD research team: iuibd@iu.edu

Closed Crohn's Disease Studies

Duration: 12 Weeks + potential to receive treatment for up to 4.5 years

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention: Ozanimod (Oral)

Possibility of Placebo: 1 in 3

Duration: All bio-specimen collections and chart reviews will continue until 2026

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Intervention: Medical chart reviews and biological specimen collection.

Duration: 3 years (2 in person visits)

Patient Population: Adult patients with newly (within 5 years) diagnosed Crohn's Disease and no disease-related complications.

Duration: One time scan (1 in person visit)

Patient Population: Adult patients with Crohn's Disease or Ulcerative Colitis fasting for 2 hours prior

Duration: Indefinite or upon withdraw

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Procedures: Patient surveys before every office visit & medical chart reviews

Duration: 1 year (16 in person visits)

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention: Oral BI 706321 + Stelara

Possibility of Placebo: Yes

Duration: 16 weeks

Patient Population: Adult patients with mild to moderate Crohn's Disease and on a stable dose of medication

Study Intervention: 3 self-provided vagal nerve stimulations per day for 16 weeks

Possibility of Placebo: None

Duration: 1 year – Option to roll into the long term extension study VIVID-2

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention: Mirikizumab vs Stelara vs Placebo

Possibility of Placebo: 2 in 11

Duration: Approximately 112 weeks

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention: BMS-986165 (oral)

Possibility of Placebo: 1 in 4

Duration: 48 weeks + potential to receive up to 2 additional years of treatment

Patient Population: Adult patients with moderately to severely active Crohn’s disease

Study Intervention: Guselkumab or Ustekinumab ( IV + Subcutaneous)

Possibility of Placebo: 1 in 5